Advertisement

The Scientist

» clinical trials and evolution

Most Recent

image: Lamarck and the Missing Lnc

Lamarck and the Missing Lnc

By | October 1, 2012

Epigenetic changes accrued over an organism’s lifetime may leave a permanent heritable mark on the genome, through the help of long noncoding RNAs.

21 Comments

image: Evolving Dependence

Evolving Dependence

By | September 27, 2012

Scientists unravel the confusing molecular biology behind a fruit fly’s reliance on a single type of cactus.

1 Comment

image: Cantley Changes Jobs

Cantley Changes Jobs

By | September 14, 2012

Renowned cancer researcher Lewis Cantley is leaving Harvard to lead a new cancer center at Weill Cornell Medical College and NewYork-Presbyterian Hospital.

0 Comments

image: Scientists

Scientists "Spin" Results

By | September 13, 2012

A new study of the scientific literature finds that researchers are guilty of overemphasizing the benefits of medical treatments.

0 Comments

image: Fears over Fast-Tracking Drugs

Fears over Fast-Tracking Drugs

By | September 10, 2012

Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.

0 Comments

image: Capsule Reviews

Capsule Reviews

By | September 1, 2012

Wired for Story, Dreamland, Homo Mysterious, and Vagina

0 Comments

image: FDA to Debate Starch Treatment

FDA to Debate Starch Treatment

By | August 31, 2012

The US Food and Drug Administration will consider whether or not to stop the use of intravenous starch solutions to replace lost blood.

0 Comments

image: Epigenetic Drug Improves Cholesterol Levels

Epigenetic Drug Improves Cholesterol Levels

By | August 28, 2012

Results from a Phase II trial for cardiovascular disease with an epigenetic target therapy show promise.

1 Comment

image: Clinical Trial Misfortune

Clinical Trial Misfortune

By | August 28, 2012

A human trial of a hepatitis C treatment is shut down after one of the participants died.

1 Comment

image: Pharma Whistleblower

Pharma Whistleblower

By | August 16, 2012

A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.

1 Comment

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement
The Scientist
The Scientist